nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 481 participants.

Also called NCT01824394

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 481 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01824394
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01824394. Randomized; single masking; primary purpose treatment. Start 2013-04-01 (actual); primary completion 2017-11-26 (actual). Results posted on 2018-12-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation
Intervention (Device)
nMARQ Navigation Catheters
Intervention (Device)
NaviStar ThermoCool Catheters
Lead sponsor
Biosense Webster, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01824394
Content hash
7e1f725cd1bdb390dee60f67e71c90bfa9211f5464bcbdd9ae0c711904487038